Clinical trial
Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine…
NCT00354549 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00354549 |
|---|---|
| Title | Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC |
| Official title | Bevacizumab and Erlotinib First-Line Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (Stage IIIB/IV) Followed by Platinum-Based Chemotherapy at Disease Progression. A Multicenter Phase II Trial |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab + erlotinib hydrochloride, gemcitabine hydrochloride + cisplatin or carboplatin |
| Enrollment | 104 |
| Start date | Jan 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Sep 1, 2010 |
| First posted | Jul 20, 2006 |
| Last update posted | May 15, 2019 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: